Protective Effect of Zinc on Cyclophosphamide-Induced Hematoxicity and Urotoxicity

被引:0
作者
Adnan Ayhanci
Ruhi Uyar
Erinc Aral
Selda Kabadere
Sila Appak
机构
[1] Eskisehir Osmangazi University,Department of Biology, Faculty of Medicine, Faculty of Art and Sciences
[2] Eskisehir Osmangazi University,Department of Physiology, Faculty of Art and Sciences
[3] Eskisehir Osmangazi University,Department of Histology, Faculty of Art and Sciences
[4] Izmir Institute of Technology,Department of Molecular Biology and Genetics, Faculty of Science
来源
Biological Trace Element Research | 2008年 / 126卷
关键词
Zinc; Cyclophosphamide; Hematopoietic system; Bladder; Rat;
D O I
暂无
中图分类号
学科分类号
摘要
Cyclophosphamide (CP) is widely used for the treatment of neoplastic diseases; however, its toxicity causes dose-limiting side effects. Zinc (Zn) is an essential trace element and has important biological functions that control many cell processes including DNA synthesis, normal growth, reproduction, fetal development, bone formation, and wound healing. Therefore, the toxicity of CP and the possible protective effect of Zn on blood cells, bone marrow, and bladder of rat were investigated in this study. Intraperitoneal administration of 50, 100, or 150 mg/kg CP for 3 days caused, in a dose-dependent manner, reductions in the number of leukocytes, thrombocytes, and bone marrow nucleated cells and a serious urotoxicity. To explore whether CP-induced damages could be prevented by Zn, other groups of rats were pretreated with 4 or 8 mg/kg ZnCl2 intraperitoneally for 3 days then challenged with respective doses of CP plus ZnCl2 on day 4 for three more days. The results indicated that treatment of rats with Zn could dose-dependently alleviate CP-induced toxicities on blood cells, bone marrow cells, and urinary bladder. We suggest that Zn could be a potentially effective drug in the prevention of CP-related hematoxicity and urotoxicity.
引用
收藏
页码:186 / 193
页数:7
相关论文
共 101 条
  • [1] de Jonge ME(2005)Clinical pharmacokinetics of cyclophosphamide Clin Pharmacokinet 44 1135-1164
  • [2] Huiteman ADR(1984)Cyclophosphamide (cytoxan): a review on relevant pharmacology and clinical use J Am Acad Dermatol 11 1115-1126
  • [3] Rodenhuis S(1991)Cyclophosphamide toxicity: characterizing and avoiding the problem Drugs 42 781-795
  • [4] Beijnen JH(1973)Urological complications of cyclophosphamide Br J Urol 45 606-609
  • [5] Ahmed AR(1997)Complications of cyclophosphamide therapy Eur Arch Otorhinolaringol 254 65-72
  • [6] Hombal SM(1968)Effect of cyclophosphamide on advanced lung cancer and haematological toxicity of large, intermittent intravenous doses Can Med Assoc J 98 532-538
  • [7] Fraiser LH(2007)Pathophysiological aspects of cyclophosphamide and ifosfamide induced hemorrhagic cystitis; implication of reactive oxygen and nitrogen species as well as PARP activation Cell Biol Toxicol 23 303-312
  • [8] Kanekal S(1997)Prevention and treatment of hemorrhagic cystitis Pharmacotherapy 17 696-706
  • [9] Kehrer JP(1992)Hemorrhagic cystitis complicating bone marrow transplantation Mayo Clin Proc 67 128-130
  • [10] Watson NA(2005)Zinc, oxidant-triggered cell signaling, and human health Mol Aspects Med 26 245-255